|1.||Kutner, Andrzej: 4 articles (01/2015 - 01/2002)|
|2.||Milczarek, Magdalena: 2 articles (01/2015 - 10/2008)|
|3.||Wietrzyk, Joanna: 2 articles (01/2015 - 10/2008)|
|4.||Chodyński, Michał: 1 article (01/2015)|
|5.||Pietraszek, Anita: 1 article (01/2015)|
|6.||Trynda, Justyna: 1 article (01/2015)|
|7.||Turlej, Eliza: 1 article (01/2015)|
|8.||Studzinski, George P: 1 article (07/2012)|
|9.||Chen-Deutsch, Xiangwen: 1 article (07/2012)|
|10.||Harrison, Jonathan S: 1 article (07/2012)|
01/01/2015 - "Analogs of 1,25-dihydroxyergocalciferol, modified in the side-chain and in the A-ring, were tested for their antiproliferative activity against a series of human cancer cell lines in vitro and in vivo toxicity. "
10/01/2008 - "PRI-1906 inhibited the tumor growth at doses 1 and 5 microg/kg per day, and PRI-2191 only at the dose 5 microg/kg per day. "
11/01/1999 - "Analogues PRI-1906, PRI-1907, PRI-1909, PRI-2191, PRI-2192, PRI-2193 and PRI-2194 were examined for their antiproliferative activity in vitro against a spectrum of various human cancer cell lines using the MTT technique. "
10/01/2008 - "Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model."
07/01/2012 - "Differentiation induced by 1α,25-dihydroxyvitamin D3 (1,25D) or its analogs PRI-1906 and PRI-2191 was enhanced by QVD to a varying degree, depending on the subtype of the leukemia. "
01/01/2002 - "PRI-1906, an analog of vitamin D2, and PRI-2191, an analog of vitamin D3 bind nuclear vitamin D receptor (nVDR) with substantially lower affinity than 1,25-dihydroxyvitamin D3 (1,25-D3), but have higher differentiation-inducing activity as estimated in HL-60 leukemia cellmodel. "
01/01/2005 - "We showed that pre-treatment with calcitriol or one of its side-chain-modified analogs PRI-1906 or PRI-2191 caused resistance of HL-60 promyelocytic leukemia cells to genistein-, doxorubicin-, cisplatin-, and taxol-induced apoptosis. "
01/01/2005 - "In this paper, we examined the effects of treatment with calcitriol or its side-chain-modified analogs, analog of Vitamin D2, coded PRI-1906, with monohomologated and unsaturated side-chain and the analog of Vitamin D3, coded PRI-2191, with (24R) hydroxyl group, and those of known cytostatics (genistein, etoposide, doxorubicin, cisplatin, and taxol) on the apoptosis of HL-60 promyelocytic leukemia cells. "
|3.||Hypercalcemia (Milk Alkali Syndrome)
08/01/1994 - "Progressively increased serum 1,25-dihydroxyvitamin D2 concentration in a hypoparathyroid patient with protracted hypercalcemia due to vitamin D2 intoxication."
11/01/1993 - "When normocalcemia had been attained, intravenous hyperalimentation was started, in which 1,000 U vitamin D2 was inadvertently supplemented on days 5-18, On days 15-18, hypercalcemia rapidly recurred, accompanied by markedly increased serum levels of 25-OHD2 (9.1 ng/dl) and 1,25-(OH)2D2 (161 pg/ml). "
11/01/1993 - "Increased 1,25-(OH)2D2 concentration in a patient with malignancy-associated hypercalcemia receiving intravenous hyperalimentation inadvertently supplemented with vitamin D2."
|4.||Vitamin D Deficiency
|5.||Prostatic Neoplasms (Prostate Cancer)
|2.||1 alpha,24-dihydroxyvitamin D3 (Tacalcitol)
|5.||Cholecalciferol (Vitamin D3)
|8.||Calcitriol Receptors (Calcitriol Receptor)
|1.||Total Parenteral Nutrition